Adaptive Biotechnologies Corp — Investor Relations & Filings

Adaptive Biotechnologies Corp. is a commercial-stage company focused on immune-driven medicine. It specializes in decoding the adaptive immune system to develop clinical products for diagnosing and treating diseases. The company operates an Immune Medicine Platform that sequences T-cell and B-cell receptors to generate immune receptor data. This data is applied across life sciences research, clinical diagnostics, and drug discovery. A key offering is clonoSEQ, a highly sensitive, next-generation sequencing (NGS) assay for assessing Minimal Residual Disease (MRD) in certain blood cancers. This product is utilized in both clinical practice and biopharmaceutical drug trials. The company aims to harness the immune system's natural capabilities as a tool to transform disease detection and treatment.